Pipelinepharma is a global online marketplace that directly connects pharmaceutical buyers and sellers to facilitate licensing deals for oncology products. The marketplace lists over 1,376 oncology finished dosages and 1,067 APIs available for licensing, as well as 120 clients seeking in-licensing opportunities. Pipelinepharma aims to make licensing more efficient by removing intermediaries and enabling deals to be made in just a few days through their online platform.
This document discusses pharmaceutical licensing in respiratory therapeutics. It notes that the global respiratory market is expected to be worth $24.5 billion by 2015. Patent expirations and generic competition have slowed the market growth rate. In 2008, the top 5 companies (GlaxoSmithKline, Merck, AstraZeneca, Novartis) contributed 48% of global sales. The document also describes Pipelinepharma, an online marketplace that connects buyers and sellers of pharmaceutical products and dossiers to facilitate licensing deals. Pipelinepharma lists over 28,000 registered products available for in-licensing or distribution.
Generic Pharma 2.0 Masters of Business Development & MarketingGeneric Pharma 2.0
Introduction to Generic Pharma 2.0
- Business Development Toolkit
- Portfolio Consulting
- Digital Marketing
- Lead Generation & Conversion
- Design & Creative
New Pharma Magazine is holding its launch party in New York City on March 14th during DCAT Week. The magazine is the premier source for news, events, and lifestyle insights for decision makers in the pharmaceutical industry. Key industry leaders such as Ed Borkowski and Stu Williams will attend the exclusive cocktail event at the W Hotel New York along with the president of Generic Pharma 2.0. New Pharma Magazine focuses on engaging readers on strategic issues facing the changing pharmaceutical industry.
Pipelinepharma is a global online marketplace that directly connects pharmaceutical buyers and sellers to facilitate licensing deals for oncology products. The marketplace lists over 1,376 oncology finished dosages and 1,067 APIs available for licensing, as well as 120 clients seeking in-licensing opportunities. Pipelinepharma aims to make licensing more efficient by removing intermediaries and enabling deals to be made in just a few days through their online platform.
This document discusses pharmaceutical licensing in respiratory therapeutics. It notes that the global respiratory market is expected to be worth $24.5 billion by 2015. Patent expirations and generic competition have slowed the market growth rate. In 2008, the top 5 companies (GlaxoSmithKline, Merck, AstraZeneca, Novartis) contributed 48% of global sales. The document also describes Pipelinepharma, an online marketplace that connects buyers and sellers of pharmaceutical products and dossiers to facilitate licensing deals. Pipelinepharma lists over 28,000 registered products available for in-licensing or distribution.
Generic Pharma 2.0 Masters of Business Development & MarketingGeneric Pharma 2.0
Introduction to Generic Pharma 2.0
- Business Development Toolkit
- Portfolio Consulting
- Digital Marketing
- Lead Generation & Conversion
- Design & Creative
New Pharma Magazine is holding its launch party in New York City on March 14th during DCAT Week. The magazine is the premier source for news, events, and lifestyle insights for decision makers in the pharmaceutical industry. Key industry leaders such as Ed Borkowski and Stu Williams will attend the exclusive cocktail event at the W Hotel New York along with the president of Generic Pharma 2.0. New Pharma Magazine focuses on engaging readers on strategic issues facing the changing pharmaceutical industry.
The document is a promotional kit for co-exhibitors at a pharmaceutical licensing pavilion at a trade show. It highlights the benefits of exhibiting collaboratively at the pavilion such as increased networking opportunities and return on investment compared to exhibiting alone. It describes the location and facilities of the pavilion including private meeting rooms and networking areas. Floor plans of the pavilion layout are also included showing the arrangement of the different networking stations.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
Pfizer is facing significant challenges as many of its blockbuster drug patents expire in the coming years. This will open the door for cheaper generic competition that will eat into Pfizer's revenues. As CEO, I would [1] focus R&D on developing new blockbuster drugs to replace revenue losses, [2] look for strategic acquisitions of companies with promising drug pipelines, and [3] strengthen Pfizer's portfolio of treatments for chronic diseases to take advantage of demographic trends. With successful execution of these strategies, Pfizer could remain the world's most valued pharmaceutical company.
An article featured in our new New Pharma Magazine to be released in February. Stay tuned for details on how to subscribe to this cutting edge industry publication.
This document provides information on various over-the-counter licensing products categorized by therapeutic class and approval type. It includes summaries of cosmetic and medical device products for skin care, feminine hygiene, and fertility testing. Products like the Nanodermix Nanoanti-Age cream, nSkin wrinkle treatments, Esui feminine wash, Donna fertility tester, Donna Glove, and Multi-Gyn vaginal health products are highlighted.
This document contains 3 short summaries:
1) It summarizes statistics on how people access information online, with most using search engines and some using social media.
2) It summarizes statistics on people's concerns about data privacy when using different methods to access information online.
3) It summarizes statistics on how people recognize technology companies, with most recognizing Google and some recognizing other large companies.
The Magazine for Decision Makers in a Global Industry.
Look for the pre-launch edition coming in December 2011!
content@genericlicensing.com if you're interested in contributing editorial content, advertisement and/or advertorials.
Wörwag Research and Development GmbH is a subsidiary of Wörwag Pharma Group dedicated to developing generic, OTC, and new chemical entity products and medical devices according to European guidelines. Its business model involves licensing out its developed products in Europe and worldwide. The document provides readily compiled dossiers for several generic drug products that have received German and European marketing authorizations and are available for submission in other markets. It also outlines ongoing development projects and provides contact information.
This confidential presentation from Neogen in April 2011 discusses their API development and product selection process. Neogen develops and licenses out pharmaceutical products to generic companies wishing to expand their portfolios but lacking skills or willingness to undertake development. Their development process includes market intelligence, formulation, manufacturing facilities selection, regulatory strategy, and clinical testing for some products. They have first mover advantage on several products launched via various dosage forms developed both in-house and through production partners in Europe. Key personnel are introduced with relevant experience in the pharmaceutical industry.
This document summarizes Astron Research Ltd, a featured developer in the Global Generic Product Directory. Astron is an Indian pharmaceutical company established in 2001 that develops and manufactures generic pharmaceutical products. It has dossiers for over 100 molecules ready or in development for global markets. Astron has capabilities across the pharmaceutical value chain including API manufacturing, finished dose production, marketing and distribution. It is seeking partnerships for product development and commercialization.
This document is the 3rd edition of the Global Generic Product Directory, which contains information on generic pharmaceutical products and their developers. It has more products, developers, and data than previous editions. The directory aims to help users license generic products by providing contact information for developers. It can be accessed online for the latest product and company information. The founder of Genericlicensing Limited, which created the directory, encourages users to provide feedback on how to improve the resource.
Healgel is an innovative skin care gel developed by UK plastic surgeons to promote skin healing and reduce scar appearance. It contains ingredients that soothe, repair, and prevent scarring. A survey of 141 people found that 94% reported Healgel was very soothing, 82% had reduced swelling, and 85% found it highly effective at reducing discoloration. The gel's effectiveness comes from ingredients that stimulate collagen production, encourage cell renewal, seal the skin surface, and reduce itching and puffiness. Users reported the gel helped scars heal quickly and comfortably and reduced acne scarring.
This document summarizes a presentation about analyzing the biosimilars market. It discusses how interchangeability is a major hurdle for biosimilar uptake compared to generics. It analyzes growth statistics for the biologics market and shows it is concentrated in western markets, while most of the world's population is in developing markets. Future opportunities for biosimilars growth are seen in the US, EU, and India due to factors like pricing pressures and market entry barriers. Key therapeutic areas and where to invest are also discussed.
The document discusses a joint project between GlaxoSmithKline, GEA Pharma Systems, and Siemens to develop a continuous manufacturing solution for tablet production. The project was completed in just six months and proved that continuous manufacturing can produce tablets continuously and reliably with real-time quality monitoring. This approach uses significantly less space than traditional batch processes and improves manufacturing efficiency. The success of the project demonstrated that continuous manufacturing has potential to transform pharmaceutical production.
This document proposes a licensing-focused pavilion at the CPhI Worldwide Frankfurt trade show in October 2011. [1] The pavilion would promote licensing companies together to attract more clients than exhibiting individually. [2] Exhibiting in the pavilion would provide marketing and promotion for 12 months before and after the show as well as on-site support like catering and meetings with top clients. [3] Companies interested in the pavilion must be involved in licensing and book space soon as places are limited.
Opportunities and barriers in the biosimilar marketevolution or revolution fo...Generic Pharma 2.0
This document discusses the opportunities and barriers in the biosimilar drug market. While biosimilars could generate billions in sales, their development faces significant challenges compared to traditional generics. Biosimilars are biologic drugs whose development requires clinical testing due to variations in production, unlike traditional generics. Their high development costs of $10-40 million mean price discounts must be smaller. Physicians may also be cautious to adopt biosimilars. For generics companies to succeed in biosimilars, they will need to adopt new business models focused on marketing and distribution, rather than frequent low-cost drug launches. The top biosimilar targets are expected to be erythropoietin, G-CSF, interferons,
The document is a promotional kit for co-exhibitors at a pharmaceutical licensing pavilion at a trade show. It highlights the benefits of exhibiting collaboratively at the pavilion such as increased networking opportunities and return on investment compared to exhibiting alone. It describes the location and facilities of the pavilion including private meeting rooms and networking areas. Floor plans of the pavilion layout are also included showing the arrangement of the different networking stations.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
Pfizer is facing significant challenges as many of its blockbuster drug patents expire in the coming years. This will open the door for cheaper generic competition that will eat into Pfizer's revenues. As CEO, I would [1] focus R&D on developing new blockbuster drugs to replace revenue losses, [2] look for strategic acquisitions of companies with promising drug pipelines, and [3] strengthen Pfizer's portfolio of treatments for chronic diseases to take advantage of demographic trends. With successful execution of these strategies, Pfizer could remain the world's most valued pharmaceutical company.
An article featured in our new New Pharma Magazine to be released in February. Stay tuned for details on how to subscribe to this cutting edge industry publication.
This document provides information on various over-the-counter licensing products categorized by therapeutic class and approval type. It includes summaries of cosmetic and medical device products for skin care, feminine hygiene, and fertility testing. Products like the Nanodermix Nanoanti-Age cream, nSkin wrinkle treatments, Esui feminine wash, Donna fertility tester, Donna Glove, and Multi-Gyn vaginal health products are highlighted.
This document contains 3 short summaries:
1) It summarizes statistics on how people access information online, with most using search engines and some using social media.
2) It summarizes statistics on people's concerns about data privacy when using different methods to access information online.
3) It summarizes statistics on how people recognize technology companies, with most recognizing Google and some recognizing other large companies.
The Magazine for Decision Makers in a Global Industry.
Look for the pre-launch edition coming in December 2011!
content@genericlicensing.com if you're interested in contributing editorial content, advertisement and/or advertorials.
Wörwag Research and Development GmbH is a subsidiary of Wörwag Pharma Group dedicated to developing generic, OTC, and new chemical entity products and medical devices according to European guidelines. Its business model involves licensing out its developed products in Europe and worldwide. The document provides readily compiled dossiers for several generic drug products that have received German and European marketing authorizations and are available for submission in other markets. It also outlines ongoing development projects and provides contact information.
This confidential presentation from Neogen in April 2011 discusses their API development and product selection process. Neogen develops and licenses out pharmaceutical products to generic companies wishing to expand their portfolios but lacking skills or willingness to undertake development. Their development process includes market intelligence, formulation, manufacturing facilities selection, regulatory strategy, and clinical testing for some products. They have first mover advantage on several products launched via various dosage forms developed both in-house and through production partners in Europe. Key personnel are introduced with relevant experience in the pharmaceutical industry.
This document summarizes Astron Research Ltd, a featured developer in the Global Generic Product Directory. Astron is an Indian pharmaceutical company established in 2001 that develops and manufactures generic pharmaceutical products. It has dossiers for over 100 molecules ready or in development for global markets. Astron has capabilities across the pharmaceutical value chain including API manufacturing, finished dose production, marketing and distribution. It is seeking partnerships for product development and commercialization.
This document is the 3rd edition of the Global Generic Product Directory, which contains information on generic pharmaceutical products and their developers. It has more products, developers, and data than previous editions. The directory aims to help users license generic products by providing contact information for developers. It can be accessed online for the latest product and company information. The founder of Genericlicensing Limited, which created the directory, encourages users to provide feedback on how to improve the resource.
Healgel is an innovative skin care gel developed by UK plastic surgeons to promote skin healing and reduce scar appearance. It contains ingredients that soothe, repair, and prevent scarring. A survey of 141 people found that 94% reported Healgel was very soothing, 82% had reduced swelling, and 85% found it highly effective at reducing discoloration. The gel's effectiveness comes from ingredients that stimulate collagen production, encourage cell renewal, seal the skin surface, and reduce itching and puffiness. Users reported the gel helped scars heal quickly and comfortably and reduced acne scarring.
This document summarizes a presentation about analyzing the biosimilars market. It discusses how interchangeability is a major hurdle for biosimilar uptake compared to generics. It analyzes growth statistics for the biologics market and shows it is concentrated in western markets, while most of the world's population is in developing markets. Future opportunities for biosimilars growth are seen in the US, EU, and India due to factors like pricing pressures and market entry barriers. Key therapeutic areas and where to invest are also discussed.
The document discusses a joint project between GlaxoSmithKline, GEA Pharma Systems, and Siemens to develop a continuous manufacturing solution for tablet production. The project was completed in just six months and proved that continuous manufacturing can produce tablets continuously and reliably with real-time quality monitoring. This approach uses significantly less space than traditional batch processes and improves manufacturing efficiency. The success of the project demonstrated that continuous manufacturing has potential to transform pharmaceutical production.
This document proposes a licensing-focused pavilion at the CPhI Worldwide Frankfurt trade show in October 2011. [1] The pavilion would promote licensing companies together to attract more clients than exhibiting individually. [2] Exhibiting in the pavilion would provide marketing and promotion for 12 months before and after the show as well as on-site support like catering and meetings with top clients. [3] Companies interested in the pavilion must be involved in licensing and book space soon as places are limited.
Opportunities and barriers in the biosimilar marketevolution or revolution fo...Generic Pharma 2.0
This document discusses the opportunities and barriers in the biosimilar drug market. While biosimilars could generate billions in sales, their development faces significant challenges compared to traditional generics. Biosimilars are biologic drugs whose development requires clinical testing due to variations in production, unlike traditional generics. Their high development costs of $10-40 million mean price discounts must be smaller. Physicians may also be cautious to adopt biosimilars. For generics companies to succeed in biosimilars, they will need to adopt new business models focused on marketing and distribution, rather than frequent low-cost drug launches. The top biosimilar targets are expected to be erythropoietin, G-CSF, interferons,
Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Pharma in licensing competition hotting up
1. Pharmaceutical Licensing Overview 2010
Creative Solutions Needed as
Pharmaceutical In-licensing
Competition Heats-Up
Continued demand for innovative and potentially first-in-class medicines is driving up the
cost and driving down the potential return on investment for late stage in-licensing deals,
pushing the pharmaceutical industry to be more creative as it tries to lessen the impact of
patent expiries, finds independent market analyst Datamonitor*.
The number of healthcare-focused licensing deals entered into by the top 10 pharmaceutical
companies in 2009 rose by 12% over the previous year. With the pharmaceutical industry seeking
to reshape its development pipeline amid widespread cost-cutting and restructuring of internal
R&D activities, deal numbers are expected to continue growing.
Martin Adams, senior healthcare analyst at Datamonitor, comments: “The annual increase in in-
licensing deal activity confirms that Big Pharma is actively seeking acquisitions and licensing
agreements as a more cost-effective means of gaining access to novel products than carrying out
extensive in-house R&D.”
However, as companies compete to secure late stage deals that offer a short to mid-term solution
to the pending patent cliff of 2011, the cost of acquisitions is inevitably rising.
Martin adds: “Companies of all sizes have to be far more creative and flexible in their approach to
securing the best deal terms if they want to maintain healthy returns on investment (ROI) and, as
a result, relationships between Big Pharma and its partners are becoming increasingly dynamic.
Traditional licensing deals, for example, continue to be replaced by option arrangements or
heavily back-ended deal structures.”
Another consequence is that as competition for the most attractive candidates intensifies, would-
be licensees are being forced to look at either less commercially attractive late-stage drugs, or
earlier-stage licensing opportunities. In 2008-09, 57% of all product in-licensing deals involved
drug candidates at the earliest stages of development (pre-clinical).
“The structure of these early-stage deals is evolving with licensees becoming more risk-averse
and placing increasing emphasis on commercial milestone payments (back-loading) supporting
smaller upfront fees” adds Martin.
Datamonitor also expects out-licensing deals, which have been relatively sparse historically, to
rise over the coming years as Big Pharma seeks local marketing expertise to increase the
regional commercial prospects of marketed products and free up resources and cash that can be
put to other uses.
The global generics industry has evolved significantly over the past decade; it has become an
increasingly integral element of the prescription pharmaceutical sector and, helped by aggressive
M&A strategies, its two leading players—Teva and Sandoz—sit just below the Big Pharma peer
2. set in terms of scale.
Simon King, pharmaceutical analyst at Datamonitor, comments: “Sales growth has been driven by
two key factors; growing demand for cheaper pharmaceuticals as a means to contain healthcare
expenditure and a succession of patent expirations on heavily prescribed branded ‘blockbuster’
products, which the generics industry has capitalized on.
“As a result, a robust period of growth for the generics industry has run concurrent to an
‘indifferent’ performance for the much of the branded pharmaceutical sector.”
However, Datamonitor forecasts that sales growth for the generics industry will begin to slow, with
a CAGR of 5.0% forecast for the period 2009–15. Closer analysis reveals that a deceleration in
sales growth will take hold from 2012 onwards as demonstrated by a global CAGR of 3.7% for the
period 2012–15 versus a 6.3% CAGR for the period 2009–12.
This pattern maps to the widely perceived end of Big Pharma’s ‘patent cliff’, with 2012 often
viewed as a nadir given the anticipated loss of exclusivity for the branded industry’s biggest
selling product—Pfizer’s $12 billion-a-year Lipitor (atorvastatin) franchise—in late 2011.
Simon concludes: “In short, the level of branded revenues associated with blockbuster products
that have become exposed to the generics industry via patent expiration will begin to decrease
sharply from 2012 onwards.
“This sharp decline—driven partly by a fall in Big Pharma’s blockbuster productivity over the past
decade—will deprive the generic industry of significant revenue injections. The end of this ‘golden
era’ of patent expiries will fundamentally shift the generics landscape as sections of the wider
pharmaceutical market become more commoditized.”
Ends
Find out more with Datamonitor's Pharmaceutical Licensing
Overview 2010!
If you have any questions regarding this report please feel free to email us. Alternatively contact
us on +1 312 416 2834 or 44 (0) 161 238 4040 for more information.